Pfizer Inc PFE:NYSE (Common Stock)

LastDaily Change / % ChangeDividend YieldVolumeAvg Volume (10 day)
33.32 0.17   0.51%3.86%9,294,21314.7M
Market data is delayed by at least 15 minutes.
Summary chart showing the current equity's performance of over the past 1 days
  • Advanced Charts
  • Embed the above chart in your blog or website

    Customize, copy, and then paste the generated code into your website.

Chart as of 03:25 PM ET 8/23/2017

Latest News Headlines for Pfizer Inc

Clinical and Regulatory Progress Boosting Biotech Sector

MarketNewsUpdates.com News Commentary PALM BEACH, Florida, August 22, 2017 /PRNewswire/ -- The biotech sector is continuing to elevate its performance behind clinical and regulatory advancements as industry leaders develop the latest drugs and technologies as well as their respective drug candidates approach the finish line or move towards getting a green light to proceed. Escalating technological advancements in last few years has enabled Companies to introduced new systems that are anticipated to accomplish chromatographic events in less time and deliver more thorough results. Advancing biotechs this week include: Moleculin Biotech, Inc., (NASDAQ: MBRX), Pfizer Inc. (NYSE: PFE), Merck & Co. (NYSE: MRK), AVEO Pharmaceuticals Inc. (NASDAQ: AVEO), Sucampo Pharmaceuticals Inc. (NASDAQ: SCMP)

Alliance Foundation Trials Opens Global Trial Investigating First-in-Class Palbociclib in HR+, HER2+ Metastatic Breast Cancer

IBRANCE is an oral inhibitor of CDKs 4 and 6,(2) which are key regulators of the cell cycle that trigger cellular progression.(3,4) In the U.S., IBRANCE is indicated for the treatment of HR+, HER2- advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine based therapy in postmenopausal women, or fulvestrant in women with disease progression following endocrine therapy. Including the U.S., IBRANCE is approved in more than 65 countries.

Bristol-Myers Squibb and Pfizer to Highlight Commitment to Reducing the Risk of Stroke Caused by Non-Valvular Atrial Fibrillation (NVAF) and Treating Deep Vein Thrombosis/Pulmonary Embolism (DVT/PE) at ESC Congress 2017

PREGNANCY CATEGORY B -- There are no adequate and well-controlled studies of ELIQUIS in pregnant women. Treatment is likely to increase the risk of hemorrhage during pregnancy and delivery. ELIQUIS should be used during pregnancy only if

View more recent headlines

Peers Information HelpPFE Pfizer Inc vs. Peers

PFE
Pfizer Inc
0.86%
Roche Holding Ltd. (ADR)
9.29%
Novartis AG (ADR)
13.98%
Merck & Co., Inc.
5.27%
Sanofi SA (ADR)
19.24%
PFE
Pfizer Inc
3.84%
Roche Holding Ltd. (ADR)
3.27%
Novartis AG (ADR)
3.26%
Merck & Co., Inc.
3.02%
Sanofi SA (ADR)
3.40%
PFE
Pfizer Inc
0.51%
-0.06%
Roche Holding Ltd. (ADR)
-0.13%
Novartis AG (ADR)
-0.14%
Merck & Co., Inc.
-0.43%
Sanofi SA (ADR)
Compare these stocks

Latest Annual and Quarterly SEC Filings

More Filings
10-K

This report contains detailed information about the company's business finances and management.

10-Q

Quarterly reports contain financial statement, a discussion from management and a list of company events (stock splits, acquisitions, etc.)

Company Background

Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines and vaccines, as well as products for consumer healthcare. IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology, rare diseases and consumer healthcare. EH includes legacy brands, branded generics, generic sterile injectable products, biosimilars and infusion systems. EH also includes a research and development (R&D) organization, as well as its contract manufacturing business. Its brands include Prevnar 13, Xeljanz, Eliquis, Lipitor, Celebrex, Pristiq and Viagra.

http://www.pfizer.com

Loading...

collapse, right-facing arrow indicating collapsed view of sectionOverview

A table providing an overview of the stock
Bid | Size-- | --
Ask | Size-- | --
Price Open33.07
Previous Close33.15
Day High33.39
Day Low33.07
52 Week High8/24/2016 | 35.38
52 Week Low11/3/2016 | 29.83
% Off 52 Week High-5.82%
% Off 52 Week Low11.70%
Beta (5 Yr)1
Volatility Avg8/22/2017 | 15.12
10-Day Avg. Volume14,722,190
Market data is delayed by at least 15 minutes.

expand, down-facing arrow indicating expanded view of sectionFundamentals

A table providing the fundamentals of the stock
EPS (TTM)7/2/2017 | 1.37
P/E Ratio7/2/2017 | 23.9
Market CapLarge Cap | 198.42B
Shares Outstanding5.96B
Float5.9B

collapse, right-facing arrow indicating collapsed view of sectionDividends

A table providing information about the dividends of the stock
Dividend Yield3.86%
Ex-Date8/2/2017
Dividend Announcement6/22/2017
Date of Record8/4/2017
Payable$0.32 - QRTR
Payable Date9/1/2017

collapse, right-facing arrow indicating collapsed view of sectionShare Statistics

A table providing statistics about shares of the stock
Shares Short43.17M
Short Ratio2.6
Short % of Float0.73%
As of 7/31/2017
The performance data quoted represents past performance. Past performance does not guarantee future results. Current performance may be lower or higher than the performance quoted. Investment return and principal value of an investment will fluctuate and when redeemed, the investment may be worth more or less than their original cost.
The research, tools, and information provided will not include every security available to the public.